Document is current
Any future updates will be listed below
-
Authors
Xu, Yaling
Guo, Xiaojing
Chen, Meimei
Ricci, Francesca
Salomone, Fabrizio
Murgia, Xabier
Sun, Bo
- License Information
-
More Information
Article History
Received: 22 January 2022
Revised: 18 May 2022
Accepted: 26 May 2022
First Online: 14 June 2022
Competing interests
: This research was supported by Chiesi Farmaceutici S.p.A, which owns the marketing rights for Poractant alfa and patent rights of CHF5633. F.R. and F.S. are Chiesi Farmaceutici employees. X.M. is a Chiesi consultant. The company contributed to the study design but had neither influence on the performance, analysis, and interpretation of experimental data nor in writing the manuscript.
: Patient consent was not required for this study.
